Syra Health Seeks Shareholder Approval for Significant Equity Plan Expansion

summarizeSummary

Syra Health Corp. filed its definitive proxy statement, seeking shareholder approval for the election of directors, auditor ratification, and a significant expansion of its equity incentive plan, which could result in over 23% potential dilution.

check_boxKey Events · Corporate Governance and Compliance · SYRA

• Annual Meeting Scheduled

  Shareholders will convene on July 23, 2026, to vote on key corporate governance matters, including director elections and auditor ratification.

• Equity Incentive Plan Expansion Proposed

  The company seeks to amend its 2022 Omnibus Equity Incentive Plan to increase the total number of Class A shares available for issuance to 4,100,000.

• Significant Potential Dilution

  If all 4,100,000 shares authorized under the expanded plan were issued, it would represent approximately 23.64% dilution to the current outstanding shares (including Class B equivalent).

• Routine Governance Proposals

  Shareholders will also vote on the election of five directors and the ratification of M&K CPAS, PLLC as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis · SYRA · Trade & Services

Syra Health Corp. is asking shareholders to approve a substantial increase in its 2022 Omnibus Equity Incentive Plan, raising the total shares available for awards to 4,100,000 Class A shares. While intended to attract and retain talent, this authorization represents a potential dilution of approximately 23.64% if all these shares were issued, which is a significant overhang for existing shareholders, especially for a company with a market capitalization of approximately $6.0 million. This proposal follows the company's recent announcement of its first profitable quarter, which could be seen as management leveraging improved sentiment to secure future compensation flexibility.